Peripheral Arterial Disease Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Peripheral Arterial Disease Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including Peripheral Arterial Disease clinical trials and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Discover the latest drugs and treatment options in the Peripheral Arterial Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Peripheral Arterial Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Peripheral Arterial Disease Pipeline Report
• In November 2024:- CSL Behring- A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
• In November 2024:- Eli Lilly and Company- The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
• DelveInsight's Peripheral Arterial Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Peripheral Arterial Disease treatment.
• The leading Peripheral Arterial Disease Companies such as Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
• Promising Peripheral Arterial Disease Therapies such as Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others
Stay ahead with the most recent pipeline outlook for Peripheral Arterial Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peripheral Arterial Disease Treatment Drugs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Peripheral Arterial Disease Emerging Drugs Profile
• Semaglutide: Novo Nordisk
Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.
• VM202: Helixmith
VM202 is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith's non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Peripheral Artery Disease.
• Revacept: AdvanceCor
Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.
Explore groundbreaking therapies and clinical trials in the Peripheral Arterial Disease Pipeline. Access DelveInsight's detailed report now! @ New Peripheral Arterial Disease Drugs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Peripheral Arterial Disease Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Unveil the future of Peripheral Arterial Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peripheral Arterial Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Peripheral Arterial Disease Pipeline Report
• Coverage- Global
• Peripheral Arterial Disease Companies- Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
• Peripheral Arterial Disease Therapies- Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others
• Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Peripheral Arterial Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peripheral Arterial Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Peripheral Arterial Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Arterial Disease - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral Arterial Disease Collaboration Deals
9. Late Stage Products (Phase III)
10. Semaglutide: Novo Nordisk
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VM202: Helixmith
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. Revacept: AdvanceCor
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Peripheral Arterial Disease Key Companies
20. Peripheral Arterial Disease Key Products
21. Peripheral Arterial Disease Unmet Needs
22. Peripheral Arterial Disease Market Drivers and Barriers
23. Peripheral Arterial Disease Future Perspectives and Conclusion
24. Peripheral Arterial Disease Analyst Views
25. Peripheral Arterial Disease Key Companies
26. Appendix
List of Top Selling Market Research Reports in 2024
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peripheral Arterial Disease Pipeline Therapeutics Assessment Report 2024 (Updated) here
News-ID: 3764760 • Views: …
More Releases from DelveInsight Business Research LLP
Epilepsy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epilepsy Pipeline Insight 2024" report provides comprehensive insights about 85+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive Epilepsy Pipeline Report to stay informed about the latest…
Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "Diffuse Large B-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment Report 20 …
(Albany, United States) As per DelveInsight's assessment, globally, the Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
To explore more information on the latest breakthroughs in the Chronic Obstructive Pulmonary Disease Pipeline treatment landscape of the report, click here @ Chronic Obstructive…
Biliary Tract Cancer Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
More Releases for Disease
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…